Bei Wang

发表

Platform model describing pharmacokinetic properties of vc-MMAE antibody–drug conjugates

Jin Y. Jin, L. Gibiansky, S. Girish, 2017, Journal of Pharmacokinetics and Pharmacodynamics.

Clinical pharmacology of vc-MMAE antibody–drug conjugates in cancer patients: learning from eight first-in-human Phase 1 studies

S. Girish, Shang-Chiung Chen, B. Fine, 2019, mAbs.

Development and Translational Application of an Integrated, Mechanistic Model of Antibody-Drug Conjugate Pharmacokinetics

K. Gadkar, S. Ramanujan, S. Sukumaran, 2016, The AAPS Journal.

Results of a Dose‐Finding Phase 1b Study of Subcutaneous Atezolizumab in Patients With Locally Advanced or Metastatic Non–Small Cell Lung Cancer

M. Burotto, E. Felip, E. Pozzi, 2021, Clinical pharmacology in drug development.

Pharmacokinetics and Exposure-Response Analysis of Venetoclax + Obinutuzumab in Chronic Lymphocytic Leukemia: Phase 1b Study and Phase 3 CLL14 Trial

M. Hallek, L. Gibiansky, A. Salem, 2021, Advances in Therapy.

Phase I Study of DSTP3086S, an Antibody-Drug Conjugate Targeting Six-Transmembrane Epithelial Antigen of Prostate 1, in Metastatic Castration-Resistant Prostate Cancer.

H. Scher, C. Higano, D. Danila, 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Analyzing Patient-Reported Outcomes in Breast Cancer throughItem-Response Theory Pharmacometric Modeling

Jin Y. Jin, M. Karlsson, S. Girish, 2015 .

A phase I study of pharmacokinetics of trastuzumab emtansine in Chinese patients with locally advanced inoperable or metastatic human epidermal growth factor receptor 2-positive breast cancer who have received prior trastuzumab-based therapy

Shang-Chiung Chen, Jian Zhang, Xichun Hu, 2020, Medicine.

Pharmacokinetic and exposure–response analysis of pertuzumab in patients with HER2-positive metastatic gastric or gastroesophageal junction cancer

M. Shah, Yoon-Koo Kang, M. Alsina, 2019, Cancer Chemotherapy and Pharmacology.

Pharmacokinetic (PK) and exposure-response (ER) analysis of pertuzumab (P) in patients (pts) with HER2-positive metastatic gastroesophageal junction and gastric cancer (mGEJC/GC).

M. Shah, J. Tabernero, Yoon-Koo Kang, 2018 .

Development of a Subcutaneous Fixed‐Dose Combination of Pertuzumab and Trastuzumab: Results From the Phase Ib Dose‐Finding Study

M. Kågedal, C. Wynne, I. Nijem, 2018, Journal of clinical pharmacology.

Correction to: Population pharmacokinetics of trastuzumab emtansine in previously treated patients with HER2-positive advanced gastric cancer (AGC)

S. Girish, Shang-Chiung Chen, M. Kågedal, 2017, Cancer Chemotherapy and Pharmacology.

Pharmacokinetics of pertuzumab administered concurrently with trastuzumab in Chinese patients with HER2-positive early breast cancer.

Yang Luo, Bing-he Xu, V. Tjan-Heijnen, 2019, Anti-cancer drugs.

Immunogenicity assays for antibody-drug conjugates: case study with ado-trastuzumab emtansine.

Surinder Kaur, Montserrat Carrasco-Triguero, Zhihua Julia Qiu, 2013, Bioanalysis.

Catabolic fate and pharmacokinetic characterization of trastuzumab emtansine (T-DM1): an emphasis on preclinical and clinical catabolism.

P. LoRusso, S. Girish, J. Tibbitts, 2012, Current drug metabolism.

Clinical pharmacology of trastuzumab emtansine (T-DM1): an antibody–drug conjugate in development for the treatment of HER2-positive cancer

Dan Lu, Amita Joshi, Patricia M. LoRusso, 2012, Cancer Chemotherapy and Pharmacology.

Population pharmacokinetics of trastuzumab emtansine in previously treated patients with HER2-positive advanced gastric cancer (AGC)

S. Girish, Shang-Chiung Chen, M. Kågedal, 2017, Cancer Chemotherapy and Pharmacology.

Ethnic sensitivity assessment of the antibody–drug conjugate trastuzumab emtansine (T-DM1) in patients with HER2-positive locally advanced or metastatic breast cancer

S. Girish, Michael W. Lu, I. Nijem, 2016, Cancer Chemotherapy and Pharmacology.

Population pharmacokinetics of trastuzumab emtansine (T-DM1), a HER2-targeted antibody–drug conjugate, in patients with HER2-positive metastatic breast cancer: clinical implications of the effect of covariates

M. Cobleigh, S. Girish, P. Conte, 2014, Cancer Chemotherapy and Pharmacology.

An Integrated Multiple-Analyte Pharmacokinetic Model to Characterize Trastuzumab Emtansine (T-DM1) Clearance Pathways and to Evaluate Reduced Pharmacokinetic Sampling in Patients with HER2-Positive Metastatic Breast Cancer

H. Burris, S. Girish, I. Krop, 2013, Clinical Pharmacokinetics.

Effects of Trastuzumab Emtansine (T‐DM1) on QT Interval and Safety of Pertuzumab Plus T‐DM1 in Patients With Previously Treated Human Epidermal Growth Factor Receptor 2–Positive Metastatic Breast Cancer

P. LoRusso, S. Girish, A. Joshi, 2013, Clinical pharmacology in drug development.

Prediction of Human Pharmacokinetics of Antibody–Drug Conjugates From Nonclinical Data

S. Girish, A. Kamath, S. Prabhu, 2019, Clinical and translational science.

Clinical Implications of Pathophysiological and Demographic Covariates on the Population Pharmacokinetics of Trastuzumab Emtansine, a HER2‐Targeted Antibody‐Drug Conjugate, in Patients With HER2‐Positive Metastatic Breast Cancer

P. LoRusso, M. Beeram, S. Girish, 2012, Journal of clinical pharmacology.

Population pharmacokinetic and exploratory exposure–response analysis of the fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection in patients with HER2-positive early breast cancer in the FeDeriCa study

S. Girish, S. Hennig, M. Kågedal, 2021, Cancer Chemotherapy and Pharmacology.

A Pharmacometric Analysis of Patient-Reported Outcomes in Breast Cancer Patients Through Item Response Theory

M. Karlsson, S. Girish, L. Friberg, 2018, Pharmaceutical Research.

Pharmacokinetic and exploratory exposure–response analysis of pertuzumab in patients with operable HER2-positive early breast cancer in the APHINITY study

J. Baselga, G. von Minckwitz, D. Fumagalli, 2019, Cancer Chemotherapy and Pharmacology.

Drug interaction potential of trastuzumab emtansine (T-DM1) combined with pertuzumab in patients with HER2-positive metastatic breast cancer.

H. Burris, S. Girish, J. Cortés, 2012, Current drug metabolism.

Exposure–response analyses of trastuzumab emtansine in patients with HER2-positive advanced breast cancer previously treated with trastuzumab and a taxane

S. Girish, Shang-Chiung Chen, A. Joshi, 2017, Cancer Chemotherapy and Pharmacology.

Abstract P1-18-03: Pertuzumab (P) plus high-dose trastuzumab (H) for the treatment of central nervous system (CNS) progression after radiotherapy (RT) in patients (pts) with HER2-positive metastatic breast cancer (MBC): Primary efficacy analysis results from the phase II PATRICIA study

N. Ibrahim, M. Pegram, A. Nicholas, 2020 .

Exposure–efficacy relationship of trastuzumab emtansine (T-DM1) in EMILIA, a phase III study of T-DM1 versus capecitabine (X) and lapatinib (L) in HER2-positive locally advanced or metastatic breast cancer (MBC).

S. Swain, M. Untch, S. Girish, 2013 .

Platform model describing pharmacokinetic properties of vc-MMAE antibody–drug conjugates

L. Gibiansky, S. Girish, Shang-Chiung Chen, 2017, Journal of Pharmacokinetics and Pharmacodynamics.

Exposure–safety relationship of trastuzumab emtansine (T-DM1) in patients with HER2-positive locally advanced or metastatic breast cancer (MBC).

S. Swain, M. Untch, S. Girish, 2013 .

P. LoRusso, M. Beeram, S. Girish, 2012, Journal of clinical pharmacology.

Population pharmacokinetics and CD20 binding dynamics for mosunetuzumab in relapsed/refractory B‐cell non‐Hodgkin lymphoma

P. Chanu, Bei Wang, M. Marchand, 2024, Clinical and translational science.